Pakistan journal of pharmaceutical sciences最新文献

{"title":"Pharmacodynamic basis of gabapentin combined with Hegu-point catgut embedding for post-herpetic neuralgia.","authors":"Li-Ping Li, Zong-Zhou Song, Yang Zheng, Ting Wu, Fang-Wei Li, Yan Huang","doi":"10.36721/PJPS.2026.39.5.152.1","DOIUrl":"10.36721/PJPS.2026.39.5.152.1","url":null,"abstract":"<p><strong>Background: </strong>Post-herpetic neuralgia (PHN) is a common refractory complication of herpes zoster, characterized by persistent neuropathic pain that seriously impairs patients' quality of life.</p><p><strong>Objectives: </strong>The study aimed to assess the clinical effects of gabapentin when administered in combination with Hegu-point catgut embedding in patients suffering from post-herpetic neuralgia (PHN).</p><p><strong>Methods: </strong>A randomized, assessor-blinded study was conducted, wherein a total of 210 PHN patients were equally divided into two groups: 1) the control group receiving only gabapentin and 2) the combination group that received combined therapy of gabapentin and Hegu-point catgut embedding weekly. After 4 weeks of treatment, pain intensity, sleep quality, serum biomarkers, clinical efficacy and adverse events were evaluated.</p><p><strong>Results: </strong>After 4 weeks, both groups displayed a significant reduction in Visual Analogue Scale (VAS) and Pittsburgh Sleep Quality Index (PSQI) scores, with greater improvement reported in the combination group (P < 0.05). In addition, both groups showed a significant decrease in serum levels of substance P, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), while β-endorphin levels showed a significant increase. The changes were found to be more pronounced in the combination group (P < 0.05). Interestingly, the combination group demonstrated a higher overall response rate (92.38% vs 80.00%) and fewer adverse events (12.38% vs 26.67%, P < 0.05).</p><p><strong>Conclusion: </strong>Altogether, combination therapy provided superior short-term improvement in symptoms and biomarker modulation as compared to gabapentin alone. Since the present study only assessed peripheral serum markers, the underlying mechanistic pathways could not be deciphered. Additionally, longer-term outcomes of therapy were not assessed, serving as a major limitation of this study.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1611-1617"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of cetylpyridinium chloride mouthwash combined with triamcinolone acetonide on oral microbiota and the Th17/Treg balance in patients with oral lichen planus.","authors":"Lingshan He, Quanqiang Zhong, Xinfeng Zhang, Tianyi Li","doi":"10.36721/PJPS.2026.39.6.162.1","DOIUrl":"10.36721/PJPS.2026.39.6.162.1","url":null,"abstract":"<p><strong>Background: </strong>Oral lichen planus (OLP) is a chronic inflammatory disease associated with oral microbiome imbalance and immune dysregulation.</p><p><strong>Objectives: </strong>To evaluate the effects of CPC mouthwash combined with triamcinolone acetonide on oral microbiota and Th17/Treg balance in erosive OLP patients.</p><p><strong>Methods: </strong>This study involved 80 patients with erosive OLP from January 2023 to January 2025. They were divided into: A control group treated with triamcinolone acetonide and a combination group treated with triamcinolone acetonide plus cetylpyridinium chloride mouthwash. After 4 weeks, primary outcomes included clinical efficacy, visual analog scale (VAS) pain scores, changes in signs and erosive area, oral salivary bacteria detection rate, Th17/Treg ratio, serum adipokine chemerin and cytokine levels (IL-17, TNF-α, IL-10) and OHIP-14 scores. Secondary outcomes were adverse reaction incidence and recurrence rates during follow-up.</p><p><strong>Results: </strong>The combination group showed better outcomes after 4 weeks of treatment. The total effective rate was 95%, higher than the control group's 80% (P=0.022). The combination group had superior pain relief (P=0.024), better mucosal repair (P=0.002) and a significant decrease in erosive area (P=0.021). It also had lower oral detection rates of Staphylococcus and Candida albicans (P<0.05). Immunologically, the combination therapy significantly reduced serum levels of chemerin, Th17 cells, Th17/Treg ratio, IL-17 and TNF-α (P<0.001), while increasing Treg cells and IL-10 levels (P=0.003), indicating stronger anti-inflammatory and immune-balancing effects. The combination group showed a greater reduction in the OHIP-14 score (P < 0.001), indicating improved oral health-related quality of life. No significant difference in adverse reactions was observed (P>0.05) and all were mild. The combination group had a lower recurrence rate within 3 months post-treatment, although the difference was not statistically significant (P=0.521).</p><p><strong>Conclusion: </strong>The combination of cetylpyridinium chloride mouthwash with triamcinolone acetonide effectively regulates the oral microbiota structure and restores the Th17/Treg immune balance in OLP patients.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1708-1720"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteome-based identification and validation of NXPE3 in childhood acute lymphoblastic leukaemia.","authors":"Najia Tabassum, Yamna Khurshid, Basir Syed, Aftab Ahmed, Sadia Muhammad, Rehan Imad, Talat Mirza","doi":"10.36721/PJPS.2026.39.6.176.1","DOIUrl":"10.36721/PJPS.2026.39.6.176.1","url":null,"abstract":"<p><strong>Background: </strong>Childhood acute lymphoblastic leukaemia (cALL) tends to metastasize to central nervous system. Treatment with antileukemic agents against CNS leukaemia is an essential component for cure in ALL. Hence, it is essential to identify biomarkers for CNS infiltration. Proteomics, supported by mass spectrometry, is the platform for exploring biomarkers in various biological samples, contributing to translational research.</p><p><strong>Objectives: </strong>This study aimed to identify the plasma proteome profile of children across different risk groups of cALL. Neurexophilin and PC-esterase family, member 3 (NXPE3), was validated. The protein-protein interactions (PPI) of NXPE3 were evaluated with bioinformatics analyses.</p><p><strong>Methods: </strong>Plasma samples from 15 patients with B-ALL standard risk (SR), B-ALL high risk (HR) and T-ALL high risk (HR), were analysed using LC-MS/MS. NXPE3 protein was validated in all risk groups using ELISA. To compare the NXPE3 values across groups, the Kruskal-Wallis test was applied. A p-value < 0.05 was considered significant. STRING database was used for PPI.</p><p><strong>Results: </strong>LC MS/MS analysis showed upregulation of NXPE3 in B-ALL SR. Upon ELISA validation, a high plasma concentration of NXPE3 was observed in B-ALL SR, 4.37±1.84 ng/ml (95% CI 3.31, 5.44), consistent with LC MS/MS findings. A lower concentration of NXPE3 was observed in B-ALL HR 2.68±1.34 ng/ml and T-ALL HR 2.38±0.92ng/ml. The findings were statistically significant. The PPI of NXPE3 highlighted its involvement in multiple processes, including gene expression, cytoskeletal organisation and neuronal function.</p><p><strong>Conclusion: </strong>This is the first report of NXPE3 in cALL. NXPE3 was identified as a potential biomarker for assessing CNS infiltration in cALL. Further studies are recommended to explore its role in leukemogenesis.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1854-1861"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147717562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baicalein induces cervical cancer apoptosis via PTEN/PI3K/AKT pathway modulation.","authors":"Qiong Yu, Mingyan Wang, Zhifang Li, Xiaolan Yu","doi":"10.36721/PJPS.2026.39.6.167.1","DOIUrl":"10.36721/PJPS.2026.39.6.167.1","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer continues to be a major cause of female cancer deaths globally, with dysregulation of the PTEN/PI3K/AKT pathway contributing to disease progression and treatment resistance. Baicalein, a bioactive flavonoid, exhibits anti-cancer properties through incompletely understood mechanisms.</p><p><strong>Objectives: </strong>To investigated whether baicalein promotes cervical cancer cell apoptosis by modulating PTEN expression and PI3K/AKT.</p><p><strong>Methods: </strong>In this study, we investigated the role of baicalein in promoting apoptosis in SiHa cervical cancer cells, with a focus on its potential modulation of PTEN expression and the PI3K/AKT pathway. Cell viability and apoptosis were assessed following baicalein treatment at various doses and time points. The expression levels of PTEN, PI3K, AKT, and Bcl-2 family proteins were analyzed to elucidate the molecular mechanisms. Additionally, the functional impact of PTEN overexpression, alone or in combination with baicalein, was evaluated.</p><p><strong>Results: </strong>We demonstrated that baicalein treatment (IC50 = 53.3 μmol/L) induced dose- and time-dependent cytotoxicity and increased apoptosis through modulation of Bcl-2 family proteins. Mechanistically, baicalein upregulated PTEN expression while suppressing PI3K/AKT pathway components including AKT1 and PDK1. PTEN overexpression alone inhibited PI3K/AKT signaling and induced apoptosis (31.53%). Remarkably, combining baicalein with PTEN overexpression produced synergistic effects, achieving 46.83% apoptosis and maximally suppressing pro-survival signals while activating pro-apoptotic mechanisms. The combination treatment increased the Bax/Bcl-2 ratio 40-fold and reduced AKT1 and PDK1 expression by >80%.</p><p><strong>Conclusion: </strong>Our findings reveal that baicalein enhances PTEN tumor suppressor function to inhibit PI3K/AKT signaling, and suggest that combining natural compounds with tumor suppressor restoration represents a promising therapeutic strategy for cervical cancer.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1759-1770"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ceftazidime/avibactam combined dynamic nutritional support on intestinal barrier function in sepsis patients: A focus on barrier protection mechanisms.","authors":"Xiaojuan Sha, Lijuan Sun, Jun Wu","doi":"10.36721/PJPS.2026.39.6.153.1","DOIUrl":"10.36721/PJPS.2026.39.6.153.1","url":null,"abstract":"<p><strong>Background: </strong>Studies have confirmed that the progression of sepsis is closely related to intestinal barrier dysfunction, including intestinal mucosa ischemia and hypoxia, flora imbalance and epithelial cell apoptosis. Therefore, protecting the intestinal barrier function has become a key link in the comprehensive treatment of sepsis.</p><p><strong>Objectives: </strong>This study evaluated the impact of a novel β-lactamase inhibitor compound preparation (ceftazidime/avibactam) on intestinal barrier function in sepsis patients.</p><p><strong>Methods: </strong>The study included 108 sepsis patients (January 2022‒August 2025) and grouped them as an observation group (54 cases, ceftazidime/avibactam+dynamic nutritional support) and a control group (54 cases, Ceftazidime/Sulbactam+dynamic nutritional support). Of the outcome measures assessed, the 28-day all-cause mortality was primary, while ICU length of stay, mechanical ventilation time, antibiotic course, intestinal barrier function markers (DAO, LBP, Claudin-1) and inflammatory cytokines (IL-6, TNF-α) were secondary.</p><p><strong>Results: </strong>The results indicated lower 28-day all-cause mortality in the observation group vs the control group, along with shorter ICU length of stay, mechanical ventilation time and time to negative blood culture conversion (P<0.05). Concerning post-treatment intestinal barrier function, DAO, LBP and FC were lower while claudin-1 was higher in the observation group compared to the control group (P<0.05). Analysis of inflammatory factors also showed greater reductions in IL-1β, IL-6 and TNF-α in the observation group post-treatment (P<0.05).</p><p><strong>Conclusion: </strong>Ceftazidime/Avibactam plus dynamic nutritional support is instrumental in improving the intestinal barrier function of sepsis patients and alleviating inflammatory reactions, thus enhancing life safety.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1618-1624"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platycodin D alleviates myocardial ischemia-reperfusion injury by suppressing aberrant mitophagy.","authors":"Jiang Li, Chengyang Xu","doi":"10.36721/PJPS.2026.39.6.156.1","DOIUrl":"10.36721/PJPS.2026.39.6.156.1","url":null,"abstract":"<p><strong>Background: </strong>Myocardial ischemia-reperfusion (I/R) injury represents a critical complication in cardiovascular diseases, profoundly influencing patient prognosis.</p><p><strong>Objectives: </strong>This study endeavors to elucidate the protective mechanisms and effects of Platycodin-D (PD) on myocardial ischemia-reperfusion injury (MIRI).</p><p><strong>Methods: </strong>A rat model of myocardial ischemia-reperfusion was employed to assess the impact of PD treatment on cardiac performance, myocardial injury biomarkers (CK-MB, LDH, cTnI), and infarct size. Further mechanistic insights were gained through Western blot and JC-1 staining, which analyzed the modulation of the HIF-1α/BNIP3 signaling pathway and mitochondrial autophagy by PD.</p><p><strong>Results: </strong>PD treatment markedly improved cardiac function, decreased levels of myocardial injury biomarkers (CK-MB, LDH, cTnI), and reduced infarct size. Mechanistically, PD was found to regulate the HIF-1α/BNIP3 signaling pathway, inhibit mitochondrial autophagy, and enhance mitochondrial function. Western blot and JC-1 staining confirmed that PD increases mitochondrial membrane potential and reduces the number of damaged mitochondria in cardiomyocytes.</p><p><strong>Conclusions: </strong>This study underscores the significant protective effects of Platycodin-D against myocardial ischemia-reperfusion injury, presenting a promising therapeutic approach for cardiovascular disease management.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1645-1654"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of tranexamic acid combined with octreotide in acute upper gastrointestinal bleeding: A retrospective clinical controlled study of high-risk patients.","authors":"Yuqian Zhao, Zhao Yang, Wei Song, Musong Li, Na Guan, Chenyi Zhao, Bing Liu, Fang Yuan, Jianru Jia","doi":"10.36721/PJPS.2026.39.6.172.1","DOIUrl":"10.36721/PJPS.2026.39.6.172.1","url":null,"abstract":"<p><strong>Background: </strong>Acute upper gastrointestinal bleeding (AUGIB) is a critical clinical condition with high morbidity and mortality, necessitating effective therapeutic interventions.</p><p><strong>Objectives: </strong>This study retrospectively investigated the efficacy of tranexamic acid combined with octreotide (OCT) in patients with high risk of AUGIB.</p><p><strong>Methods: </strong>A total of 183 patients with UGIB were initially enrolled, and 170 eligible patients were finally included and divided into an OCT group (n=83) and a TXA + OCT group (n=87). The main indicators compared were: drug onset time, hemostasis time, upper gastrointestinal bleeding volume, blood routine, coagulation function and clinical effective rate; secondary indicators: clinical efficacy, visual analogue scale (VAS) and adverse reactions.</p><p><strong>Results: </strong>After treatment, the onset time, hemostasis time, bleeding volume, coagulation function indexes (PT, TT, APTT and Fib) and VAS in TXA group and OCT group were significantly lower than those in OCT group. The clinical effective rate and hemoglobin, red blood cell and platelet count in TXA group and OCT group were significantly higher than those in OCT group (P<0.05). There were no significant differences in the average blood transfusion volume, hospitalization time, rebleeding rate within 3 days, surgical intervention needs and mortality between the two groups (P>0.05), but the combined group had a slight advantage. In addition, combination therapy did not increase the incidence of adverse reactions.</p><p><strong>Conclusion: </strong>These findings provide valuable clinical evidence supporting the use of tranexamic acid in combination with octreotide for AUGIB.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1817-1826"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147717508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a combination of Ginkgo biloba leaf extract and triangle health management in patients with ischemic vertigo- An exploratory investigation.","authors":"Xiuqin Shen, Ying Zhang, Jiao Wei","doi":"10.36721/PJPS.2026.39.6.179.1","DOIUrl":"10.36721/PJPS.2026.39.6.179.1","url":null,"abstract":"<p><strong>Background: </strong>Ischemic vertigo (IV) is the main clinical manifestation of posterior circulation ischemia. Extract of Ginkgo biloba leaves injection (EGBLI) is rich in flavonoids and terpene lactones, which have antioxidant, vasodilator and neuroprotective effects. Triangle Health Management optimizes resource allocation through hierarchical intervention.</p><p><strong>Objectives: </strong>This prospective study analyzed the effect of EGBLI combined with triangle health management on IV.</p><p><strong>Methods: </strong>First, n=177 patients with IV were included who received conventional treatment as a control group and another n=144 patients who received EGBLI as an observation group. The clinical efficacy of the two groups was compared and hemodynamics before and after treatment were examined. In addition, nutritional proteins and symptom improvement were compared between the two groups.</p><p><strong>Results: </strong>Comparison showed that the clinical efficacy of the observation group was better (p<0.05). Meanwhile, hemodynamics and symptom improvement after treatment in the observation group were better than those in the control group (p<0.05).</p><p><strong>Conclusion: </strong>EGBLI combined with triangle health management is an excellent therapeutic regimen for IV.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1881-1887"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147717885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative management model combined with inhaled corticosteroids in CPAP treatment of acute exacerbations of pediatric bronchial asthma: A retrospective cohort study.","authors":"Yuxiao Hu, Yajuan Chu, Qianli Guo, Wenshan Lv, Linlin Liu","doi":"10.36721/PJPS.2026.39.6.163.1","DOIUrl":"10.36721/PJPS.2026.39.6.163.1","url":null,"abstract":"<p><strong>Background: </strong>Continuous positive airway pressure (CPAP) for treating acute pediatric bronchial asthma exacerbations rises yearly. Inhaled corticosteroids (ICS) are key for controlling asthma-related inflammation, but research on ICS combined with the collaborative management model (CMM) remains incomplete.</p><p><strong>Objectives: </strong>This study aims to explore the effect of CMM combined with ICS in CPAP treatment for children with acute bronchial asthma exacerbations.</p><p><strong>Methods: </strong>107 children with acute bronchial asthma exacerbations receiving CPAP in our hospital's Respiratory Department (Jan 2023-Jan 2025) were screened; 104 were included after exclusions. Based on the records of medical record treatment, they were divided into ICS group (51 cases) and CMM+ICS group (combined group, 53 cases).</p><p><strong>Primary outcomes: </strong>pulmonary function [forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF)], arterial blood gas [Arterial partial pressure of oxygen (PaO₂), arterial partial pressure of carbon dioxide (PaCO₂), oxygen saturation (SaO₂)] and CPAP-related complication incidence.</p><p><strong>Secondary outcomes: </strong>vital signs [respiratory rate (RR), heart rate (HR), blood pressure (BP)], hospital stay length, duration of a single management session, incremental cost-effectiveness ratio (ICER), pediatric asthma quality of life questionnaire (PAQLQ) scores and parental self-rating anxiety scale (SAS) anxiety levels.</p><p><strong>Results: </strong>Results showed that the combined group had significantly higher FEV1, PEF, PaO₂ and SaO₂ than the ICS group (all p<0.05), whereas PaCO₂ (p<0.001) and CPAP complication incidence (p=0.024) were lower than the ICS group. Additionally, the combined group had significantly lower RR, HR, SBP and DBP (all p<0.05), significantly shorter hospital stay and duration of a single management session (both p<0.001) and a significantly favorable ICER (-225.13 yuan/day) than the ICS group. Moreover, it had significantly higher PAQLQ scores (p<0.001) and lower parental SAS scores (p<0.001) compared with the ICS group.</p><p><strong>Conclusion: </strong>CMM combined with ICS in CPAP improves pediatric acute asthma exacerbations, has high clinical value, worthy of respiratory promotion.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1721-1734"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of an RP-HPLC method for simultaneous determination of sitagliptin and valsartan.","authors":"Muhammad Waqas, Muhammad Zaman, Huma Hameed, Waqar Siddique, Ahmad Salawi, Yosif Almoshari, Jawaher Abdullah Alamoudi","doi":"10.36721/PJPS.2026.39.6.165.1","DOIUrl":"10.36721/PJPS.2026.39.6.165.1","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus and hypertension are commonly coexisting diseases and combination therapies are required to improve therapeutic outcomes and patient compliance.</p><p><strong>Objectives: </strong>Current research aims to develop and validate a precise reverse-phase High-Performance Liquid Chromatography (RP-HPLC) method for the concurrent determination of sitagliptin and valsartan.</p><p><strong>Methods: </strong>For analysis, an Agilent 1260 Infinity II HPLC system provided with a C-18 column was used. The method was validated as per the ICH guidelines.</p><p><strong>Results: </strong>Calibration curves confirmed excellent linearity for sitagliptin and valsartan with RN^² values exceeding 0.99. The limits of detection (LOD) and quantification (LOQ) were calculated as 8.5 ppm and 25.7 ppm for sitagliptin and 7.8 ppm and 23.5 ppm for valsartan, respectively. Recovery studies and robustness confirmed method accuracy and indicated no significant impact from small variations in chromatographic parameters.</p><p><strong>Conclusion: </strong>In conclusion, this validated RP-HPLC method is consistent and efficient for compliance with pharmaceutical standards.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"39 6","pages":"1744-1750"},"PeriodicalIF":0.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}